secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001285550-23-000114
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q3 revenue $5.8M (+12% YoY); biologics & drug delivery up 55% to $3.5M
--------------------------------------------------------------------------------

- Revenue $5.8M, +12% YoY; biologics & drug delivery $3.5M (+55%) driven by preclinical services.
- Gross margin 57% vs 71% prior year due to lower-margin preclinical services and facility transition.
- Operational cash burn $1.8M, lowest since 2020; cash $24.3M at Sept 30.
- FY 2023 revenue guidance narrowed to $23-25M, representing 11-18% growth.
- Entered new strategic biologics agreements; submitted three stereotactic products and updated software to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/0001285550-23-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/clpt-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001285550-23-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer